Clinigen Group plc operates as a specialty pharmaceutical and services company. Its Clinigen Clinical Trial Services segment supplies and manages commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs, and rescue therapies. The company's Idis Managed Access segment is involved in the consultancy, development, management, and implementation of managed access programs for biotechnology and pharmaceutical companies. Its Idis Global Access segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these drugs. The company's Clinigen Specialty Pharmaceuticals segment manufactures and distributes its own and in-licensed specialist, and hospital-only medicines worldwide. It offers Ethyol for reducing the incidence of dry mouth in patients undergoing high dose radiation treatment; Cardioxane, a cardioprotective agent that is used to prevent the cardiotoxicity of anthracycline chemotherapy for patients with advanced or metastatic breast cancer; Savene and Totect, which are used as emergency treatments for extravasation at the site of injection of oncology treatment; and Foscavir, an anti-viral targeting human herpes viruses and is used primarily in bone marrow transplant patients. Its Link Healthcare business distributes pharmaceutical products in South Africa and the Asia-Pacific. The company has a strategic alliance with Cumberland Pharmaceuticals Inc. Clinigen Group plc was incorporated in 2008 and is headquartered in Burton-on-Trent, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Drug Delivery
Sub-IndustryN/A
SectorMedical
SymbolLON:CLIN
CUSIPN/A
Phone+44-1283-495010
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins7.15%
Return on Equity8.14%
Return on Assets4.26%
Miscellaneous
EmployeesN/A
Outstanding Shares122,220,000
Market Cap£1.12 billion
Clinigen Group (LON:CLIN) Frequently Asked Questions
What is Clinigen Group's stock symbol?
Clinigen Group trades on the London Stock Exchange (LON) under the ticker symbol "CLIN."
How often does Clinigen Group pay dividends? What is the dividend yield for Clinigen Group?
Clinigen Group declared a dividend on Thursday, September 27th. Stockholders of record on Thursday, November 8th will be given a dividend of GBX 3.84 per share on Friday, November 30th. This represents a dividend yield of 0.46%. The ex-dividend date is Thursday, November 8th. This is a positive change from Clinigen Group's previous dividend of $1.76. The official announcement can be accessed at this link. View Clinigen Group's Dividend History.
How were Clinigen Group's earnings last quarter?
Clinigen Group PLC (LON:CLIN) posted its earnings results on Tuesday, February, 27th. The company reported $21.20 earnings per share for the quarter, beating analysts' consensus estimates of $20.30 by $0.90. The firm earned $167.80 million during the quarter. Clinigen Group had a net margin of 7.15% and a return on equity of 8.14%. View Clinigen Group's Earnings History.
What price target have analysts set for CLIN?
6 equities research analysts have issued 12 month price objectives for Clinigen Group's shares. Their predictions range from GBX 1,160 to GBX 1,470. On average, they expect Clinigen Group's share price to reach GBX 1,265 in the next twelve months. This suggests a possible upside of 46.0% from the stock's current price. View Analyst Price Targets for Clinigen Group.
What is the consensus analysts' recommendation for Clinigen Group?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Clinigen Group in the last year. There are currently 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Clinigen Group.
Who are some of Clinigen Group's key competitors?
Some companies that are related to Clinigen Group include Agios Pharmaceuticals (AGIO), HYPERA S A/S (HYPMY), Mediclinic International (MDC), Medidata Solutions (MDSO), MEDNAX (MD), HUTCHISON CHINA/S (HCM), ABLYNX NV/ADR (ABLX), DiaSorin (DIA), Amedisys (AMED), Immunomedics (IMMU), Taro Pharmaceutical Industries (TARO), ABCAM PLC/ADR (ABCZY), Cantel Medical (CMD), Ultragenyx Pharmaceutical (RARE) and ConvaTec Group (CTEC).
Who are Clinigen Group's key executives?
Clinigen Group's management team includes the folowing people:
- Mr. Shaun Edward Chilton, CEO & Director (Age 50)
- Mr. Martin Abell, CFO & Director
- Ms. Debra Ainge, Chief Operating Officer
- Matt Parrish, Head of Investor Relations
- Mr. David Bryant, Director of Corp. Devel.
How do I buy shares of Clinigen Group?
Shares of CLIN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Clinigen Group's stock price today?
One share of CLIN stock can currently be purchased for approximately GBX 866.50.
How big of a company is Clinigen Group?
Clinigen Group has a market capitalization of £1.12 billion.
What is Clinigen Group's official website?
How can I contact Clinigen Group?
Clinigen Group's mailing address is Pitcairn House Crown Square, First Avenue, STAFFORDSHIRE, DE14 2WW, United Kingdom. The company can be reached via phone at +44-1283-495010.
MarketBeat Community Rating for Clinigen Group (LON CLIN)
MarketBeat's community ratings are surveys of what our community members think about Clinigen Group and other stocks. Vote "Outperform" if you believe CLIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
